Production of Affinity Reagents for Human Transcription Factors (U54) | Apply Online

Opportunity Summary:

The NIH Common Fund funding opportunity RFA-RM-10-017, titled "Production of Affinity Reagents for Human Transcription Factors (U54)," was a discretionary NIH initiative to create one or more centralized production centers that could generate renewable, high-quality affinity reagents targeting essentially the full set of human transcription factors. The core idea was to build a standardized, broadly usable community resource: a reliable collection of binding reagents (for example, antibodies or other affinity binders) that researchers across many fields could use to detect, localize, and capture transcription factor proteins. While the FOA emphasized broad utility across multiple experimental contexts, it made clear that the top scientific priority use case was chromatin immunoprecipitation (ChIP), reflecting the need for dependable reagents to map transcription factor-DNA interactions and regulatory networks.

A key expectation of this program was that awardees would function like production hubs rather than traditional single-lab research projects. Applications were expected to propose an end-to-end, scalable pipeline covering several linked stages: acquiring and evaluating appropriate immunogens for human transcription factors (such as proteins, domains, peptides, or other antigen formats), generating and selecting affinity reagents against those targets, and then performing rigorous biochemical characterization and validation. The FOA placed weight on validation because transcription factors can be low abundance, share conserved domains, and exist in multiple isoforms or post-translationally modified states, all of which can create specificity problems that undermine downstream assays. The centers were therefore expected to deliver reagents that were not only produced at scale, but also tested in ways that demonstrate fitness-for-purpose, especially for ChIP, and potentially also for protein detection in complex samples, immunohistochemical labeling in tissues, and immunoprecipitation or other affinity-capture workflows.

Because this was framed as a production activity, the FOA emphasized high-throughput capacity, consistency, and continuous process improvement over the life of the award. Successful applicants were expected to show how the center would use scale to reduce per-reagent cost, increase throughput, and improve quality control, including refining methods and operational steps as lessons emerged during production. At the same time, the FOA explicitly required scientific flexibility. Transcription factors vary widely in tractability, and some targets are difficult due to instability, poor immunogenicity, high homology with other family members, or challenges related to conformational epitopes. Centers were expected to anticipate these issues and adapt strategies as hard targets were encountered, rather than limiting output to only the easiest proteins.

Another central component was access and distribution. NIH framed the resulting affinity reagents as a public research tool resource, so applicants were expected to propose a realistic distribution plan aligned with NIH policies and designed to ensure broad availability and wide accessibility with minimal constraints. In practical terms, this means the program cared not only about producing reagents, but also about getting them into the hands of the wider research community in a way that supports reuse, comparability across labs, and long-term value as a shared set of tools.

Administratively, this opportunity used the U54 Cooperative Agreement mechanism, meaning NIH expected substantial programmatic involvement beyond standard grant oversight, consistent with the coordination and milestone-driven nature of building a national-scale reagent resource. The FOA was posted in early December 2010, with an application closing date of February 4, 2011, and it was later archived in March 2011. The estimated total funding amount listed was $4,000,000, with an award ceiling of $2,600,000. There was no cost sharing or matching requirement. The activity category was Health, and the CFDA number associated with the program was 93.310 (Trans-NIH Research Support).

Eligibility was broad and included a wide mix of applicant types across academia, nonprofits, for-profits (other than small businesses were explicitly noted as eligible, and small businesses were also listed), and government entities at multiple levels. The FOA listed public and private institutions of higher education, nonprofits with and without 501(c)(3) status, state and local governments (including counties, cities or townships, special district governments), independent school districts, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and a range of other categories. Additional eligible groups explicitly included Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, regional organizations, eligible federal agencies, and even non-U.S. entities (foreign organizations), signaling an intent to attract the strongest operational capability regardless of sector, and potentially to support international participation where appropriate.

In plain terms, the opportunity was designed to solve a persistent bottleneck in transcription factor research: the lack of standardized, well-validated, renewable affinity reagents that work reliably in demanding assays like ChIP. By funding production centers with industrial-style throughput, strong validation practices, and a distribution strategy that keeps tools broadly accessible, NIH aimed to create a durable platform resource that would accelerate studies of gene regulation, cell state, development, and disease by making transcription factor measurement and mapping far more reproducible across the research community.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Technology Development for New Affinity Reagents Against the Human Proteome (U54)

Previous opportunity: NIAID Resource Related Research Projects for AIDS, Allergy, Immunology and Transplantation (R24)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA RM 10 017

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA RM 10 017) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 10 017", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.